Good day, and thank you for standing by. Welcome to the Prime Medicine Wilson Disease KOL Event Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I ...
Monopar Therapeutics Inc. presented new data on its drug candidate ALXN1840 (tiomolybdate choline) for Wilson disease at the European Association for the Study of the Liver International Liver ...
Wilson's disease is a rare and potentially fatal genetic disorder caused by mutations in the ATP7B gene, which impair the body's ability to eliminate excess copper. As copper builds up-primarily in ...
The hepatic symptoms of Wilson’s disease are diverse, ranging from asymptomatic or accidental liver abnormalities to cirrhosis and acute liver failure, and they can onset at any age. The later the age ...
Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results. The market for Wilson Disease ...
Zinc blocks the intestinal absorption of copper from the diet and the reabsorption of endogenously secreted copper. Galzin ® (zinc acetate capsules) is now available for maintenance treatment of ...
In another example of the effect of modifier genes, Schiefermeier et al [45] tried to delineate why some patients have later-onset neurologic as well as hepatic symptoms by examining the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results